Germany’s new supply chain due diligence law (LkSG, or Lieferkettengesetz in its short form) came into force on 1 January for companies with more than 3,000 employees. This group numbers some 600 companies, according to the federal ministry for labour and social affairs, BMAS. A further 3,000 firms – those employing over 1,000 staff – will be subject to enforcement in January 2024.
Germany’s Ethical Supply Chain Rules In Force
New supply chain due diligence rules came into force this month in Germany, ensuring that every commercial business over a certain size respects social and environmental criteria. The medtech industry is receiving practical compliance advice.
More from Germany
• By
The IVD industry’s new 10-point plan for healthcare change shows that medtechs will keep calling the German government to account. Tariffs, sector resilience, digital functionality are among the pressing issues industry wants answers to.
• By
Whoever is handed the health portfolio in Germany’s new coalition government will face demands to amend the recently-enacted hospital and DRGs reform law. The medtech industry has been quick to make the case for change.
• By
Germany’s Union parties may have little alternative than to bring the SPD into a new four-year coalition, says Clifford Chance partner and life sciences legal expert Gunnar Sachs. Health policy will likely see both textural and structural changes.
• By
Germany’s government-industry healthcare industry roundtables have yielded a final report, even though the program was curtailed by the snap election. The new CDU-led government should pick up the baton, medtech industry associations say.
More from Europe
• By
Pediatric devices and IVDs are to be a priority. And the European Health Data Space regulation is seen as critical in supporting digital technologies and AI in transforming care.
• By
As deadlines approach, the regulatory landscape for medtech batteries is set to change, with an emphasis on sustainability and ethical practices.
• By
Cambridge, UK-based breath biopsy company Owlstone Medical will apply its volatile organic compound analysis platform in an attempt to develop a test for the identification and monitoring of pseudomonas aeruginosa in patients with cystic fibrosis.